Patients with symptomatic CNS metastases or leptomeningeal involvement 
Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression. 
Patients with bone metastases as the only site(s) of measurable disease 
Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease) 
Patients who have been previously treated with radioactive directed therapies 
Patients who have been previously treated with epothilone 
Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 
Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports 
Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ 
Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae 
Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits 
HIV+ patients 
Pregnant or lactating females.       
    

NCT00050349_exc_T1
Condition
CNS metastases
NCT00050349_exc_T2
Condition
leptomeningeal involvement
NCT00050349_exc_T5
Procedure
treated
NCT00050349_exc_T6
Qualifier
been stable for
NCT00050349_exc_T7
Temporal
at least six months prior to study start
NCT00050349_exc_T4
Condition
brain metastases
NCT00050349_exc_T8
Observation
history of
NCT00050349_exc_T9
Condition
brain metastases
NCT00050349_exc_T10
Procedure
head CT with contrast
NCT00050349_exc_T11
Scope
history of brain metastases
NCT00050349_exc_T12
Condition
bone metastases
NCT00050349_exc_T13
Procedure
hepatic artery chemoembolization
NCT00050349_exc_T14
Temporal
within the last 6 months
NCT00050349_exc_T15
Temporal
one month
NCT00050349_exc_T16
Observation
other sites of measurable disease
NCT00050349_exc_T17
Scope
within the last 6 months (one month if there are other sites of measurable disease
NCT00050349_exc_T18
Procedure
radioactive directed therapies
NCT00050349_exc_T19
Drug
epothilone
NCT00050349_exc_T20
Condition
peripheral neuropathy
NCT00050349_exc_T21
Condition
unresolved diarrhea
NCT00050349_exc_T22
Measurement
Grade
NCT00050349_exc_T23
Value
greater than 1
NCT00050349_exc_T24
Condition
severe cardiac insufficiency
NCT00050349_exc_T25
Drug
Coumadin
NCT00050349_exc_T26
Drug
warfarin-containing agents
NCT00050349_exc_T27
Qualifier
low dose
NCT00050349_exc_T28
Drug
warfarin
NCT00050349_exc_T29
Multiplier
1 mg or less
NCT00050349_exc_T30
Device
in-dwelling lines
NCT00050349_exc_T31
Device
in-dwelling ports
NCT00050349_exc_T32
Scope
severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less)
NCT00050349_exc_T34
Condition
another malignancy
NCT00050349_exc_T35
Temporal
within 5 years prior to study entry
NCT00050349_exc_T36
Scope
Coumadin or other warfarin-containing agents
NCT00050349_exc_T37
Condition
non-melanoma skin cancer
NCT00050349_exc_T38
Qualifier
curatively treated
NCT00050349_exc_T39
Condition
prostate cancer
NCT00050349_exc_T40
Condition
cervical cancer in situ
NCT00050349_exc_T41
Scope
non-melanoma skin cancer, prostate cancer, or cervical cancer in situ
NCT00050349_exc_T42
Observation
history of
NCT00050349_exc_T43
Condition
uncontrolled infection
NCT00050349_exc_T44
Condition
abcesses
NCT00050349_exc_T45
Condition
fistulae
NCT00050349_exc_T46
Scope
abcesses or fistulae
NCT00050349_exc_T47
Qualifier
active
NCT00050349_exc_T48
Qualifier
suspected
NCT00050349_exc_T49
Qualifier
acute
NCT00050349_exc_T50
Qualifier
chronic
NCT00050349_exc_T51
Scope
active or suspected acute or chronic
NCT00050349_exc_T52
Condition
psychiatric illness
NCT00050349_exc_T53
Condition
medical illness
NCT00050349_exc_T54
Observation
preclude study
NCT00050349_exc_T55
Observation
informed consent
NCT00050349_exc_T56
Observation
noncompliance to medical regimens
NCT00050349_exc_T57
Observation
inability to return for all scheduled visits
NCT00050349_exc_T58
Observation
unwillingness to return for all scheduled visit
NCT00050349_exc_T59
Scope
would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits
NCT00050349_exc_T60
Condition
HIV+
NCT00050349_exc_T61
Measurement
HIV
NCT00050349_exc_T62
Value
+
NCT00050349_exc_T63
Condition
Pregnant
NCT00050349_exc_T64
Condition
lactating
NCT00050349_exc_T65
Qualifier
symptomatic
NCT00050349_exc_T3
Negation
with the exception of
NCT00050349_exc_T66
Negation
except
NCT00050349_exc_T67
Temporal
previously
NCT00050349_exc_T68
Temporal
previously
NCT00050349_exc_T69
Multiplier
only site(s) of measurable disease
NCT00050349_exc_T70
Negation
unless